Company intelligence / Profile preview

Biorithm

Ownership: Private
Development stage: Preclinical

Overview

Biorithm has developed the femom remote monitoring solution for maternal and fetal health. The device and digital platform are currently in clinical investigation, with completed trials in Singapore and the UK. The company aims to support a US FDA premarket submission with ongoing clinical studies. Early results have enabled expansion into Southeast Asia and the US, focusing on improving perinatal outcomes through remote biometric monitoring.

Therapeutic areas: Women's Health
Modalities: DeviceDigital health platformData analytics software
Industry: Physiological Monitoring

Partnerships

Collaborations with healthcare institutions in Singapore and the United Kingdom for clinical trials

Beyond the preview

Go deeper on Biorithm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biorithm.

Explore the full profile